Polaryx Therapeutics names Will Charlton chief medical officer ahead of Phase 2 trial
Charlton, a pediatric endocrinologist with rare disease drug development experience, joined effective September 1, 2026 as Polaryx prepares to start its SOTERIA trial in the fourth quarter.
SEC filing